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1569-1993/CrownEarly detection of infection with Pseudomonas
aeruginosa in cystic ﬁbrosis: The Holy Grail or an
achievable goal?The notion that lung disease begins very early after birth is not
new, however, data published from the Australian Respiratory
Early Surveillance Team for Cystic fibrosis (AREST CF) has
unequivocally demonstrated that infants as young as 3 months
old diagnosed with CF following detection by newborn screening
may show early signs of structural lung disease and have
pulmonary infections, including with Pseudomonas aeruginosa
(Pa), even in the absence of respiratory symptoms [1,2].
Acquisition of Pa has long been known as a negative prognostic
factor in CF and avoiding chronic infection is considered to be
essential for patients [3]. The importance of early detection of
Pa is highlighted by reports of successful eradication by
aggressive and early anti-Pseudomonal/Pa therapy [4–7].
However, early detection of infection is challenging. The
AREST CF surveillance program relies on annual bronchos-
copy and bronchoalveolar lavage, which is neither practical
nor frequent enough to be used for reliable early detection of
infection. Upper airway swabs, cough swabs or deep pharyngeal
suction is used to attempt to indicate what organisms are present
in the lower airways, but opinion on the predictability and clinical
utility varies [8,9].
As many children with CF have their initial infection with Pa in
very early life, the median age of acquisition reported in the
AREST CF program was 26 months for children diagnosed
following detection by newborn screening [6], an accurate
indication of early infection would allow better targeted eradication
therapy. One approach that has been suggested is measuring serum
levels of anti-Pa antibodies and four articles in the Journal of
Cystic Fibrosis have recently examined this topic [10–13]. Mauch
and Levy [11] conducted a systematic review of the literature
covering the last 40 years of research into the utility of measuring
serum antibodies to Pa. The meta-analysis included studies using
different detection techniques and measuring antibodies generated
to different Pa antigens. In general they demonstrate reasonable
associations between serological and microbiological results in
established infection, but the situation is much less clear for early or
initial infection. Debate continues over which antibodies should be
measured, when should they be measured, do they reflect
pulmonary infection and how they should be used in clinical
practice. For young children and their families, blood sampling is0.1016/j.jcf.2014.08.001
Copyright © 2014 Published by Elsevier B.V. on behalf of Euroinvasive and unwelcomed so there needs to be adequate
justification for recommending additional blood tests!
1. What kind of antibodies?
Host response to initial Pa infection appears to be variable in
CF and the chronology of the immune response to Pa antigenic
determinants is not well-known. Studies have generally
measured antibody responses to individual virulence factors
or to a multiple antigenic blend of 64 different Pa antigens from
17 of the most common Pa serotypes (St-Ag) [11]. Exotoxin A,
elastase and alkaline protease are virulence factors produced by
Pa in established infection that may not be expressed in early
infections and/or may require a substantial bacterial density
before triggering an immune response to these antigens [14]. It
is generally believed that the immune response to these
antigens occurs over a longer period in comparison with
St-Ag, which may be expressed early in infection [11,14].
2. When may Pa serology be useful?
Even though the correlation between chronic Pa infection and
antibody titres is well-known [15,16] serology is not routinely
used in clinical practice. Neither is it used as an outcome variable
in most of the trials conducted in patients with chronic infection,
which are generally based on microbiological outcomes [17–19].
Moreover, the definitions of chronic infection with Pa do not
include antibody data [20]. In contrast, studies dealing with early
Pa infection appear more likely to use serological tests at
recruitment and when assessing outcome [21].
The utility of serology in predicting first Pa infection was
addressed by the Early Pseudomonas Infection Control (EPIC)
investigators. In the present issue of the Journal of Cystic
Fibrosis Daines et al. [12] report EPIC data that demonstrate
that positive serology was not able to predict isolation of
Pa from oropharyngeal cultures in the ensuing 6–12 months
among children b12 years of age previously Pa negative.
These data confirm previous experiences from AREST CF [4]
using BAL-based microbiological surveillance. In addition, in
the EPIC study there was substantial overlap in antibody levelspean Cystic Fibrosis Society. All rights reserved.
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highlights a common failing in the use of serology to detect
“infection” with Pa, namely the lack of consideration of
where the organism comes from or how an immune response
is generated. Pa is an environmental organism and a recent
genotyping study concluded that strains found in patients with
CF were a random sample of the environmental Pa population
[22]. Healthy children are exposed to these organisms and
clearly mount an antibody response against them without being
infected. Thus it is perhaps folly to suggest that the situation
would be different in children with CF. Since Pa serology does
not appear useful for predicting first Pa positivity, suggestions
to monitor antibody titres once a year in Pa-free CF patients
would appear to be of little use for clinicians.
3. How useful could serology prove in assessing the risk of
Pa recurrence following eradication treatment?
In another report from the EPIC study previously published
in the Journal of Cystic Fibrosis, Anstead et al. [10] demonstrated
that baseline serology was not significantly associated with Pa
eradication failure. Elevated antibody titres to Exotoxin A and
alkaline protease together with oropharyngeal cultures were
significantly associated with Pa recurrence during the 60-week
post-eradication follow-up period. The take-home message was
that high antibody titres at Pa detection were associated with a
greater risk of re-infection with Pa. This and other observations
indicate that serologymay complement cultures in monitoring Pa
recurrence in CF, as previously suggested [16,23].
4. Can serology predict long-term eradication outcome?
There is no current gold standard regarding determination of
successful eradication or how long a patient may remain free of
Pa. In a retrospective study published in this issue of the
Journal of Cystic Fibrosis Kappler et al. [13] demonstrated that
antibody testing one year after first Pa detection may predict
long-term eradication outcome. They showed that the absence
of antibodies on a single test one year after eradication therapy
had a good predictive value for long-term eradication and might
facilitate personalizing future eradication regimes. Given the
low sensitivity of oropharyngeal cultures at identifying first
Pa infection and the invasiveness of BAL to “prove”
eradication, an additional guide to indicate the effectiveness
of eradication therapy would be very useful. However, waiting
one year to be sure that eradication had been successfully
achieved may be too long as some patients require more than
one round of treatment to achieve eradication [6].
5. What conclusions can we draw from the published
studies and what future can we envisage?
Without doubt the role of anti-Pa antibodies will continue to
be a stimulating area of research in CF. It is intriguing to
consider the immune response to Pa in the upper airways in
both healthy children and those with CF and how this may
influence future research. In contrast to the past, serologicalresearch now appears more focused on initial Pa infection and
on monitoring eradication effectiveness. Serology could prove
useful in proposing personalized treatment especially for those
patients at high risk of treatment failure. However, a practice of
starting early eradication treatment on the sole basis of positive
anti-Pa serological studies is not supported by current clinical
studies. Further research is needed to identify how measuring
serological responses to Pa antigens may move us closer to
claiming the Holy Grail of identifying and eradicating Pa
before the die is cast and the structural damage done.References
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